Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Post author:ahusalliance Post published:December 19, 2016 Post category: Post comments:0 Comments Continue ReadingAnticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Complement, a target for therapy in inflammatory and degenerative diseases. Post author:ahusalliance Post published:December 19, 2016 Post category: Post comments:0 Comments Continue ReadingComplement, a target for therapy in inflammatory and degenerative diseases.
Current treatment of atypical hemolytic uremic syndrome Post author:ahusalliance Post published:December 19, 2016 Post category: Post comments:0 Comments Continue ReadingCurrent treatment of atypical hemolytic uremic syndrome
Development of RA101348, a Potent Cyclic Peptide Inhibitor of C5 for Complement-Mediated Diseases Post author:ahusalliance Post published:December 19, 2016 Post category: Post comments:0 Comments Continue ReadingDevelopment of RA101348, a Potent Cyclic Peptide Inhibitor of C5 for Complement-Mediated Diseases
How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome Post author:ahusalliance Post published:December 19, 2016 Post category: Post comments:0 Comments Continue ReadingHow I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome
A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. Post author:ahusalliance Post published:December 19, 2016 Post category: Post comments:0 Comments Continue ReadingA new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.
Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases Post author:ahusalliance Post published:December 19, 2016 Post category: Post comments:0 Comments Continue ReadingDesign and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases
Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Post author:ahusalliance Post published:December 19, 2016 Post category: Post comments:0 Comments Continue ReadingTailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
Prevention and treatment of atypical hemolytic uremic syndrome after kidney transplantation. Post author:ahusalliance Post published:December 19, 2016 Post category: Post comments:0 Comments Continue ReadingPrevention and treatment of atypical hemolytic uremic syndrome after kidney transplantation.
